LINC00942-Driven Chemoresistance in Gastric Cancer: Mechanisms and Research Implications

Study Background and Research Question

Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, with chemoresistance representing a persistent obstacle to effective therapy. Cisplatin (DDP) serves as a core agent in first-line regimens for advanced GC; however, primary and acquired resistance significantly limit its clinical benefits. Recent advances have highlighted the role of long non-coding RNAs (lncRNAs) in modulating chemotherapeutic responses, but the molecular mechanisms underlying their involvement in GC chemoresistance are not fully elucidated. The reference study by Jin et al. (DOI: 10.1002/ctm2.703) sought to identify critical lncRNAs associated with DDP resistance and characterize their mechanistic contributions to therapeutic failure in GC.

Key Innovation from the Reference Study

The central innovation of Jin et al.'s work lies in the identification and characterization of LINC00942 (LNC942) as a pivotal lncRNA conferring chemoresistance in GC. The study demonstrates that LNC942 upregulation in DDP-resistant GC cells promotes survival and stemness features while suppressing apoptosis. Mechanistically, LNC942 inhibits the degradation of Musashi2 (MSI2) by disrupting its interaction with SCF^β-TRCP E3 ubiquitin ligase, thereby enhancing MSI2 stability. Notably, stabilized MSI2, acting as a potential m⁶A reader, binds to and protects c-Myc mRNA in an m⁶A-dependent manner, leading to sustained oncogenic signaling and drug resistance. This axis provides a previously unrecognized regulatory network linking lncRNA expression, post-translational modification, and mRNA stability in GC chemoresistance (reference study).

Methods and Experimental Design Insights

Jin et al. conducted a comprehensive workflow integrating transcriptomic and proteomic analyses to pinpoint chemoresistance-associated lncRNAs. Key methodological steps included:

• Microarray profiling: Used to screen lncRNA expression differences between DDP-resistant and parental GC cell lines.
• qRT-PCR validation: Confirmed upregulation of candidate lncRNAs, identifying LNC942 as significantly elevated in resistant cells and patient samples with poor prognosis.
• Proteome array and RNA pull-down: Identified MSI2 as a direct binding partner of LNC942, further validated by RNA immunoprecipitation (RIP).
• Co-immunoprecipitation and ubiquitination assays: Explored the impact of LNC942 on MSI2 stability and its post-translational regulation via the SCF^β-TRCP E3 ligase.
• Functional assays: Assessed cell viability (MTS), apoptosis, and stemness (sphere formation) in vitro, and confirmed chemoresistance phenotypes in xenograft mouse models.
• m⁶A-dependent RNA-protein interaction studies: Established MSI2's role as an m⁶A reader stabilizing c-Myc mRNA, linking RNA modifications to drug resistance.

This multi-layered approach enabled the elucidation of the LNC942–MSI2–c-Myc axis and its functional relevance in chemoresistant GC.

Core Findings and Why They Matter

• LNC942 expression is a marker and driver of chemoresistance: Elevated LNC942 correlates with poor clinical outcomes and DDP resistance in gastric cancer patients (reference study).
• LNC942 prevents MSI2 degradation: By blocking SCF^β-TRCP-mediated ubiquitination of MSI2, LNC942 ensures sustained levels of MSI2—a protein implicated in stemness and oncogenic signaling.
• MSI2 enhances c-Myc mRNA stability via m⁶A recognition: Stabilized MSI2 preferentially binds c-Myc mRNA at m⁶A-modified sites, preventing its degradation and perpetuating oncogenic signaling.
• Therapeutic targeting of MSI2 resensitizes cells to cisplatin: The study demonstrates that pharmacological inhibition of MSI2 (using FK228) can overcome LNC942-induced chemoresistance, both in vitro and in xenograft models.

These findings establish a mechanistic link between lncRNA-driven post-translational control and mRNA stability, highlighting new avenues for reversing chemoresistance in GC.

Comparison with Existing Internal Articles

Recent internal reviews on MLN4924 and its applications in cancer biology research have underscored the value of targeting the neddylation pathway and cullin-RING ligase (CRL)-mediated ubiquitination processes for anti-cancer strategies. For instance, these articles describe how MLN4924 enables researchers to dissect CRL ubiquitination and neddylation pathway inhibition in solid tumor models, offering mechanistic insights relevant to therapeutic resistance. While Jin et al.'s study focuses on the prevention of MSI2 ubiquitination by LNC942, the internal literature demonstrates that selective NEDD8-activating enzyme inhibitors like MLN4924 can broadly suppress CRL activity, providing a parallel strategy for modulating protein stability in cancer cells. This convergence suggests that combining molecularly targeted agents disrupting ubiquitination (via NAE inhibition) with interventions against lncRNA-mediated resistance mechanisms could be a promising approach in preclinical research.

Limitations and Transferability

Although Jin et al.'s findings delineate a robust mechanism for LNC942-mediated chemoresistance in gastric cancer, several limitations merit consideration:

• The study predominantly uses GC cell lines and xenograft models; thus, the generalizability to patient-derived samples and other tumor types requires further validation.
• The reliance on pharmacological MSI2 inhibition (FK228) may not fully recapitulate genetic knockdown effects or off-target influences.
• While the involvement of m⁶A in c-Myc mRNA regulation is compelling, the global impact of m⁶A machinery on chemoresistance was not exhaustively explored.

Transferability to broader cancer biology contexts will depend on the conservation of the LNC942–MSI2–c-Myc axis across tumor types and therapeutic settings. Further research into combinatorial strategies integrating neddylation pathway inhibition and lncRNA-targeted interventions is warranted.

Protocol Parameters

• LncRNA/protein interaction validation: Employ RNA immunoprecipitation and pull-down assays using cell lysates from DDP-resistant and parental gastric cancer lines, as in Jin et al.
• Ubiquitination assays: Perform co-immunoprecipitation of target proteins followed by Western blot for ubiquitin, to monitor E3 ligase-mediated degradation.
• Cell viability and apoptosis assessment: Use MTS or similar viability assays and Annexin V/PI flow cytometry after drug treatments to quantify chemoresistance phenotypes.
• Xenograft tumor formation: Inject treated GC cells into immunocompromised mice; monitor tumor growth under cisplatin or combinatorial regimens to evaluate in vivo resistance and therapeutic efficacy.
• m⁶A-RNA immunoprecipitation: Apply m⁶A-specific antibodies and qPCR/NGS to measure m⁶A-modified c-Myc mRNA abundance and binding partners.

Research Support Resources

For researchers interested in dissecting protein degradation pathways or modeling neddylation pathway inhibition in solid tumor studies, MLN4924 (SKU B1036) is a well-characterized NEDD8-activating enzyme inhibitor suitable for both in vitro and in vivo workflows. According to the product information, MLN4924 offers potent, selective CRL ubiquitination inhibition and has demonstrated efficacy in tumor xenograft models. Its solubility profile and validated performance in cancer biology research make it a relevant tool for studies exploring the functional consequences of impaired ubiquitin-proteasome system activity, particularly in the context of chemoresistance and cell cycle regulation. Researchers may also consult scenario-driven guides and comparative analyses in internal resources for best practices in using MLN4924 as part of advanced experimental designs.